N/A N=194 Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)
Asthma
Primary: Methacholine Reactivity — 2.13; 1.48; 1.44; 1.60 mg/mL — p=0.51
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=114 Toric Eye Strain and Stability Study
Astigmatism
Primary: Objective Comfort Assessed by Electromyography(EMG) — 0.082; 0.047; 0.085; 0.257 volts
Phase 2 N=150 Naltrexone for At-Risk and Problem Drinking in Smoking Cessation Treatment
Hazardous Drinking · Cigarette Smoking
Primary: Percent Heavy Drinking Days — 11.1; 11.4 percentage of days
Phase 2 N=88 Thiamine as a Metabolic Resuscitator in Septic Shock
Septic Shock
Primary: Lactate Level 24 Hours After the First Study Medication Dose — 2.6; 2.5 mmol/L — p=0.40
Phase 1 N=40 Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease
Ocular GVHD
Primary: Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation — 3.50; 2.23; 0.16; 0.26 units on a scale — p=0.0019
Phase 3 N=24 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
Idiopathic Pulmonary Fibrosis · Cough
Primary: Efficacy of Thalidomide in Suppressing the Chronic Cough of Idiopathic Pulmonary Fibrosis Using the Cough Quality of Life Questionnaire. — 47.3; 55.2; 61.6; 44.5 units…
Phase 3 N=188 Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
Arthritis, Rheumatoid
Primary: Percentage of Participants With Positive Etanercept Anti-Drug Antibody (ADA) Status at Week 12 — 1.9 percentage of participants
N/A N=51 Effect of Weight Loss on Myocardial Metabolism and Cardiac Relaxation in Obese Adults
Obesity
Primary: Total Myocardial Oxygen Consumption (MVO2) — 1064; 1202; 947; 835 µmol/min
Phase 2 N=12 Study of Losartan in the Treatment of NAFLD in Children
NAFLD
Primary: Change in Alanine Aminotransferase (ALT) From Baseline to End of Treatment (8 Weeks of Treatment) — 136.44; 117.40; 112.78; 89.40 U/L
Phase 2 N=9 Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
Cigarette Smoking · Schizophrenia
Primary: Change of ExpiredCO Level From Baseline — -2.88; 9.5; -17.38; -11.5 ppm
N/A N=8 Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement
Coronary Artery Disease
Primary: Percent Stent Coverage — 1; 0; 3; 1 Participants
Phase 4 N=65 A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
Moderate to Severe Secondary Hyperparathyroidism · Stage 5 Chronic Kidney Diseases
Primary: Mean Erythropoietin Dose Per Visit — 35.8; 22.2; 22.7; 4.7 µg
N/A N=386 Regional Anesthesia Military Battlefield Pain Outcomes Study
Anxiety Disorders · Complex Regional Pain Syndrome Type II · Depressive Disorders
Primary: Neuropathic Pain Scale - Pain Intensity — 3; 3.44; 3.92; 3.04 units on the Neuropathic Pain Scale — p=<0.0001
Phase 2 N=16 Oral Immunotherapy (OIT) for Peanut Allergy
Peanut Hypersensitivity
Primary: Percentage of Subjects Achieving Tolerance as Defined by a Negative DBPCFC 4 Weeks After Discontinuation of Peanut OIT Therapy. — 89 percentage of participants
Phase 2 N=30 Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
Corneal Neovascularization · Corneal Graft Failure
Primary: Number of Participants With Graft Failure at Week 39 and 52 — 0; 1; 1; 1 Participants